USMLE® Step 1 style questions USMLE
USMLE® Step 2 style questions USMLE
A 22-year-old woman comes to the office because of fatigue and facial rash. The symptoms began several weeks ago and have been gradually worsening. The patient states that she gets a rash when she is exposed to sunlight for any significant period of time. Physical examination shows a round 4 cm (1.57 in), scaly rash on her left cheek. The patient is also found to have tender, boggy metacarpophalangeal joints of her right hand and her left knee. She is found to have a positive antinuclear antibody titer. What complication is this patient most likely to experience?
Content Reviewers:Rishi Desai, MD, MPH
In antiphospholipid syndrome, individuals produce antiphospholipid antibodies, which attack the phospholipids in the cell membrane of their own cells, or attack proteins that are bound to those phospholipids.
So antiphospholipid syndrome, or APS, is an autoimmune disease.
Antiphospholipid syndrome can be primary or secondary. Primary antiphospholipid syndrome occurs by itself, whereas secondary antiphospholipid syndrome occurs with other autoimmune diseases, especially systemic lupus erythematosus.
And just like most autoimmune diseases, antiphospholipid syndrome is more common in young females.
The exact cause of antiphospholipid syndrome isn’t known, but there are some known genetic and environmental factors.
But the presence of the mutated HLA-DR7 gene alone isn’t enough to develop antiphospholipid syndrome - an environmental trigger must also be present.
There’s a variety of potential triggers - some common ones include infections - like syphilis, hepatitis C, HIV, and malaria - drugs, like some cardiovascular drugs - including procainamide, quinidine, propranolol, and hydralazine - or antipsychotic drugs like phenytoin and chlorpromazine.
The main antiphospholipid antibody is anti-beta2-glycoprotein I, which targets the protein beta2-glycoprotein I, also called apolipoprotein H.
This protein binds to phospholipids and inhibits agglutination which is when platelets clump together to form blood clots.
So when anti-beta2-glycoprotein I binds beta2-glycoprotein I, it’s not free to do its job, and that leads to clot formation.
Another antiphospholipid antibody is anti-cardiolipin, which targets a lipid in the inner mitochondrial membrane called cardiolipin which binds beta2-glycoprotein I.
Autoantibodies might also target blood components.
In addition, individuals might develop Libman-Sacks endocarditis, which is where vegetations form, which are a mixture of immune cells and blood clots - usually on the mitral valve.
Sometimes, a part of the main clot may break free and become an embolus, which is where a blood clot travels downstream.
This is a life-threatening situation because it literally blocks blood from getting into the lungs to pick up oxygen.
- "Robbins Basic Pathology" Elsevier (2017)
- "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
- "Harrison's Principles of Internal Medicine" McGraw-Hill Medical Publishing (2004)
- "Antiphospholipid syndrome" Best Practice & Research Clinical Rheumatology (2020)
- "Antiphospholipid syndrome" Thrombosis Research (2017)
- "Diagnosis and Management of the Antiphospholipid Syndrome" New England Journal of Medicine (2018)
- "Antiphospholipid syndrome" Translational Research (2020)